Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Jeff Bezos’ Blue Origin launches landmark Mars mission in New Glenn rocket’s first big test - 2The most effective method to Go Down Abundance through Ages with Disc Rates
- 34 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- 410 Delectable Specialty Mixed drinks
- 5Italian authorities detain civilian rescue ship, German NGO says
- Europe’s Airlines Run Low on Fuel
- What loving-kindness meditation is and how to practice it in the new year
- Met Gala 2026 will celebrate fashion as an 'embodied art form': A guide to the theme, dress code, cochairs and hosting committee of the starry event
- Norovirus infections increase significantly, with positive test rates reaching 14%
- Which camera do you believe is great for first-time clients? !
- Germany's first Omani LNG shipments arrive despite Middle East disruptions
- Home Plan Tips for Seniors
- Moon fever hits DC as Artemis 2 rocket 'candle' lights up Washington Monument just 1 month before launch (photos)
- Exploring Being a parent: A Survey of \Bits of knowledge and Guidance for Guardians\ Nurturing Book
